Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Stock-Based Compensation history
Currency unavailable · from the cash flow
No Stock-Based Compensation data reported for this period type.
Stock-Based Compensation vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M USD | -33.3% | +53.3% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M USD | +70.4% | +213.9% | 108.9% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M USD | +31.2% | +73.3% | — |
| LTM Mar 2026 | $9.07M USD | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $1.88M USD | -32.3% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M USD | — | — | — |
| LTM Mar 2026 | $125K USD | -78.0% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -27.8% | +63.3% | 56.5% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.